 |
0 Diseases |  |
4 Trials |
|
4 Trials |  |
52 News |  |
| «12 |
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Metastases: This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (clinicaltrials.gov) - Jan 22, 2020
P1, N=215, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Feb 2021 --> Nov 2021 | Trial primary completion date: Feb 2021 --> Nov 2021
- | miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Metastases: This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091 (clinicaltrials.gov) - Dec 10, 2019
P1, N=40, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Feb 2021 --> Nov 2021 | Trial primary completion date: Feb 2021 --> Nov 2021 Trial completion date: Jul 2020 --> Mar 2021 | Trial primary completion date: Jun 2020 --> Dec 2020
- || ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 na (clinicaltrials.gov) - Nov 15, 2019
P2, N=260, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Jul 2020 --> Mar 2021 | Trial primary completion date: Jun 2020 --> Dec 2020 Trial completion date: May 2021 --> Dec 2021 | Trial primary completion date: May 2021 --> Dec 2021
- | ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment change, Combination therapy, Metastases: Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 na (clinicaltrials.gov) - Sep 24, 2019
P2, N=260, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: May 2021 --> Dec 2021 | Trial primary completion date: May 2021 --> Dec 2021 N=110 --> 260
- BI 754111 / Boehringer Ingelheim, BI 907828 / Boehringer Ingelheim, BI 754091 / Boehringer Ingelheim
A phase Ia/Ib, dose-escalation/expansion study of BI 907828, an MDM2-p53 antagonist, in combination with BI 754091, an anti-PD-1 antibody, and BI 754111, an anti-LAG-3 antibody, in patients with advanced solid tumors (Board 47: Level 2 - Hall D) - Sep 18, 2019 - Abstract #AACRNCIEORTC2019AACR_NCI_EORTC_479;
Secondary endpoints include OR (per iRECIST), disease control (investigator assessed; per RECIST 1.1 and iRECIST), progression-free survival (PFS); PFS rate at 12 and 24 weeks (cohort 3 only) and safety. Phase Ib will include at least 140 evaluable patients (80 patients in cohort 1 and 20 patients each in cohorts 2, 3 and 4).
- BI 754111 / Boehringer Ingelheim, BI 754091 / Boehringer Ingelheim
A Phase I, dose finding study of BI 754111, an anti-LAG-3 antibody, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumor preliminary results from the microsatellite stable (MSS) metastatic colorectal cancer (mCRC) cohort (Board 27: Level 2 - Hall D) - Sep 18, 2019 - Abstract #AACRNCIEORTC2019AACR_NCI_EORTC_460;
BI 754111 + BI 754091 was well-tolerated and showed preliminary activity in patients with previously treated MSS mCRC. Assessment of the combination in other cohorts is ongoing.
- ||| miptenalimab (BI 754111) / Boehringer Ingelheim, brigimadlin (BI 907828) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment open: A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (clinicaltrials.gov) - Jul 7, 2019
P1a/1b, N=170, Recruiting, Sponsor: Boehringer Ingelheim
Assessment of the combination in other cohorts is ongoing. Not yet recruiting --> Recruiting
- ||| miptenalimab (BI 754111) / Boehringer Ingelheim, brigimadlin (BI 907828) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
New P1 trial: A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (clinicaltrials.gov) - May 28, 2019
P1a/1b, N=170, Not yet recruiting, Sponsor: Boehringer Ingelheim
- ||| ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment open, Combination therapy, Metastases: Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 na (clinicaltrials.gov) - Mar 12, 2019
P2, N=110, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Metastases: This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (clinicaltrials.gov) - Feb 19, 2019
P1, N=215, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Trial completion date: Aug 2020 --> Feb 2021 | Trial primary completion date: Aug 2020 --> Feb 2021
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment open, Combination therapy, Metastases: This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091 (clinicaltrials.gov) - Jan 25, 2019
P1, N=40, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Aug 2020 --> Feb 2021 | Trial primary completion date: Aug 2020 --> Feb 2021 Not yet recruiting --> Recruiting
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
New P1 trial, Combination therapy, Metastases: This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091 (clinicaltrials.gov) - Dec 19, 2018
P1, N=40, Not yet recruiting, Sponsor: Boehringer Ingelheim
- |||| ezabenlimab (BI 754091) / Boehringer Ingelheim
New P2 trial, Combination therapy, Metastases: Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 na (clinicaltrials.gov) - Oct 4, 2018
P2, N=110, Not yet recruiting, Sponsor: Boehringer Ingelheim
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (clinicaltrials.gov) - Aug 3, 2018
P1, N=215, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting N=70 --> 215 | Trial completion date: Nov 2019 --> Aug 2020 | Trial primary completion date: Nov 2019 --> Aug 2020
- ||| miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment open, Combination therapy, Monotherapy, Metastases: This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer (clinicaltrials.gov) - Mar 9, 2018
P1, N=164, Recruiting, Sponsor: Boehringer Ingelheim
N=70 --> 215 | Trial completion date: Nov 2019 --> Aug 2020 | Trial primary completion date: Nov 2019 --> Aug 2020 Not yet recruiting --> Recruiting
- ||| miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
New P1 trial, Combination therapy, Monotherapy, Metastases: This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer (clinicaltrials.gov) - Feb 15, 2018
P1, N=164, Not yet recruiting, Sponsor: Boehringer Ingelheim
- || miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment change, Combination therapy, Metastases: This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (clinicaltrials.gov) - Dec 29, 2017
P1, N=75, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting N=120 --> 75
- ||| miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment open, Combination therapy, Metastases: This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (clinicaltrials.gov) - Jun 27, 2017
P1, N=120, Recruiting, Sponsor: Boehringer Ingelheim
N=120 --> 75 Not yet recruiting --> Recruiting
- ||| miptenalimab (BI 754111) / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
New P1 trial, Combination therapy, Metastases: This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (clinicaltrials.gov) - May 16, 2017
P1, N=120, Not yet recruiting, Sponsor: Boehringer Ingelheim